Peptide bispecific antibody as well as preparation method and application thereof
By conjugating biomarker-binding peptides with immunoglobulin, bispecific antibodies are formed, which solves the problems of cumbersome production process, high cost and limited flexibility in the prior art, and achieves rapid and efficient bispecific antibodies production and Enhanced targeting capabilities.
Patent Information
- Application Number
- CN202380036733.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-21
- Filing Date
- 2023-03-09
- Publication Date
- 2024-12-06
AI Technical Summary
The production process of existing bispecific antibodies is cumbersome, costly, limited flexibility, slow production speed and challenging characterization and quality control.
Using biomarker binding peptides to conjugate to immunoglobulins or their fragments through chemical or enzymatic reactions to form bispecific antibodies that can be conjugated to a variety of target biomolecules, and using bifunctional linkers to achieve peptide cyclization and protein conjugation. Combination improves the bispecificity and production efficiency of the antibody.
The rapid and effective production of bispecific antibodies is achieved, which enhances the targeting ability of the antibodies and cell phagocytosis, reduces production costs, and improves the feasibility of flexibility and quality control.
Smart Images

Figure BDA0005104001300000171 
Figure BDA0005104001300000172 
Figure BDA0005104001300000173
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to U.S. Provisional Patent Application No. 63 / 269,638, filed on March 21, 2022, the entire disclosure of which is incorporated herein by reference.
[0003] Sequence Publication Citations
[0004] The entire contents of the sequence listing file named "P24144PCT00_sequence_listing.xml" created on March 7, 2023 (file format: ST.26XML; file size: 8KB) are incorporated herein by reference. Technical Field
[0005] The present invention relates to a peptide bispecific antibody and a preparation method and application thereof. Background Art
[0006] Bispecific antibodies are the next generation of antibody-based immunotherapies that have the potential to improve clinical efficacy and safety. The first concept of bispecific antibodies was proposed by Nisonoff and colleagues in 1960. Bispecific antibodies are designed to recognize two or more different epitopes or antigens on single or multiple target cells. These multiple targeting functions allow antibodies to enhance heterogeneous targeting capabilities against tumors and generate interactions and connections between immune cells / effector cells and cancer cells to enhance immunotherapeutic activity. Bispecific antibodies can be divided into IgG-like structures and non-IgG-like structures, which are distinguished by the presence or absence of Fc-mediated effector functions. ( Figure 1). More than 100 different types of constructs have been reported, and there are now five FDA-approved bispecific antibodies on the market. Blinatumomab is the first T cell-engaging bispecific antibody approved by the FDA in 2015, which contains a dual function that binds to B-lineage leukemia CD19 and T cell CD3. This engagement mechanism redirects immune cells to engage target cells for cytotoxic killing of cancer cells. Another T cell engager binds PD-1 and CTLA4 and is currently in Phase I and Phase II clinical trials. To date, there are more than 90 bispecific antibodies in different stages of clinical and preclinical trials. To date, bispecific antibodies have shown enhanced drug response and therapeutic index compared to monoclonal antibodies. In addition, the crystallizable fragment (Fc) region of the bispecific antibody binds to cells expressing Fc receptors (such as macrophages, natural killer cells, or dendritic cells). When recognized by Fc receptors, it can trigger common immune responses (such as antibody-dependent cell-mediated cytotoxicity or complement-dependent cytotoxicity). Despite the above advantages and potential applications, the production of bispecific antibodies remains challenging, cumbersome and costly, with limited design flexibility. For example, blinatumomab costs approximately $178,000 per treatment, making it one of the most expensive oncology drugs on the market. Recently, chemical approaches to develop bispecific antibodies have emerged, but methods are still rare.
[0007] In summary, the main technical problems of the existing technology include:
[0008] The production of bispecific antibodies using traditional methods is cumbersome;
[0009] Traditional bispecific antibodies have limited production flexibility;
[0010] High production costs;
[0011] The ratio of the two binding sites of existing bispecific antibodies is usually 1:1;
[0012] The production of new bispecific antibodies is slow;
[0013] Characterization and quality control are challenging.
[0014] A robust platform is needed to rapidly and efficiently generate novel bispecific antibodies for disease treatment and diagnosis. Summary of the invention
[0015] Thus, a first aspect of the invention provides bispecific antibodies chemically or enzymatically conjugated to one or more biomarker binding peptides that are capable of simultaneously conjugating to multiple biomolecules of one or more targets.
[0016] In certain embodiments, the bispecific antibody is derived from a natural, denatured or synthetic immunoglobulin or any fragment thereof, including but not limited to IgG, IgA, IgM, nanobodies, antigen binding fragment region (Fab), single chain variable fragment (scFv) or peptibody.
[0017] In certain embodiments, the bispecific antibody is derived from a polyclonal or monoclonal antibody.
[0018] In certain embodiments, the monoclonal antibody may be an IgG antibody of any specificity from human or any other animal origin.
[0019] In certain embodiments, the monoclonal antibody and one or more biomarker binding peptides are conjugated via a chemical or enzymatic reaction.
[0020] In certain embodiments, the one or more biomarker binding peptides include 1 to 100 biomarker binding peptides per monoclonal antibody.
[0021] In certain embodiments, each biomarker binding peptide comprises at least one sequence capable of targeting one or more biomolecules, including but not limited to proteins, peptides, cell surfaces, organelles and / or any soluble substances of the same or different targets.
[0022] In certain embodiments, the biomarker binding peptide can be selected from one or more amino acid sequences of SEQ ID NO:1 to SEQ ID NO:8.
[0023] In certain embodiments, the one or more biomolecules or biomarkers that the biomarker binding peptide can target include, but are not limited to, epidermal growth factor receptor (EGFR), epithelial cell adhesion molecule (EpCAM), programmed death ligand 1 (PD-L1), integrin, human epidermal growth factor receptor 2 (HER-2), and phosphatidylinositol proteoglycan-3 (GPC3).
[0024] In certain embodiments, each bispecific antibody can be conjugated to two or more different biomolecules on the same target surface.
[0025] In certain embodiments, each bispecific antibody can be conjugated to two or more different molecules on the surface of different targets. In these embodiments, when different targets are close enough, these targets can be connected to each other through the conjugated bispecific antibodies.
[0026] In certain embodiments, the targets of the bispecific antibodies include, but are not limited to, non-living substances and living cells, such as NK cells, T cells, macrophages, dendritic cells, erythrocytes, B cells, cancer cells, viruses, bacteria, fungi, yeasts, and parasites.
[0027] In certain embodiments, the one or more biomarker binding peptides can be a linear peptide, a cyclic peptide, a stapled peptide, a branched peptide, a dendrimeric peptide, or a scaffold peptide.
[0028] In certain embodiments, the linear biomarker binding peptide can be conjugated to the N-terminus, C-terminus, disulfide bond, or any amino acid side chain of the monoclonal antibody.
[0029] In certain embodiments, the cyclic biomarker binding peptide is formed by cyclizing the biomarker binding peptide through a chemical bond between the N-terminus and the C-terminus, between one side chain and another side chain, or between one of the N-terminus and the C-terminus and a side chain, thereby forming a cyclic peptide backbone.
[0030] In certain embodiments, the chemical bond between the N-terminus and the C-terminus, between one side chain and the other chain, or between one of the N-terminus and the C-terminus and the side chain used to form the cyclic peptide backbone can be a covalent bond, a supramolecular interaction, or a disulfide bond.
[0031] In certain embodiments, the cyclic peptide backbone of the cyclic biomarker binding peptide is chemically conjugated to a region of a monoclonal antibody by chemical conjugation, and at least one sequence of one or more biomolecules capable of targeting a target is distal to the region of the monoclonal antibody to which the cyclic peptide backbone is chemically conjugated.
[0032] In certain embodiments, chemical conjugation is performed via a bifunctional linker having a first functional domain capable of cyclizing the biomarker binding peptide and a second functional domain that chemically conjugates to a region of the monoclonal antibody.
[0033] In one embodiment, the bifunctional linker is selected from an o-phthalaldehyde linker, and the biomarker binding peptide is cyclized by one of the functional domains of the o-phthalaldehyde linker through site-specific dialkylation of the sulfhydryl side chains of two cysteine residues in the biomarker binding peptide, while the other functional domain of the o-phthalaldehyde linker will form a chemical conjugation with a region of the monoclonal antibody.
[0034] A second aspect of the present invention provides a method for preparing a bispecific antibody chemically or enzymatically conjugated to one or more biomarker binding peptides, wherein the method comprises:
[0035] Providing immunoglobulin or any fragment thereof;
[0036] providing one or more biomarker binding peptides, each biomarker binding peptide comprising a sequence of one or more biomolecules capable of targeting a target; and
[0037] One or more biomarker binding peptides are conjugated to a region of an immunoglobulin or any fragment thereof by chemical or enzymatic reaction.
[0038] In certain embodiments, the immunoglobulin or any fragment thereof includes, but is not limited to, IgG, IgA, IgM, nanobody, Fab, scFv, or peptibody.
[0039] In certain embodiments, the bispecific antibody is derived from a monoclonal antibody.
[0040] In certain embodiments, the monoclonal antibody may be an IgG antibody of any specificity from human or any other animal origin.
[0041] In certain embodiments, the monoclonal antibody and the one or more biomarker binding peptides are conjugated to each other via a chemical linker.
[0042] In certain embodiments, the one or more biomarker binding peptides include 1 to 100 biomarker binding peptides per monoclonal antibody.
[0043] In certain embodiments, each biomarker binding peptide comprises at least one sequence capable of targeting one or more biomolecules, including but not limited to proteins, peptides, cell surfaces, organelles, and / or any soluble substances of the target.
[0044] In certain embodiments, the biomarker binding peptide can be selected from one or more amino acid sequences of SEQ ID NO:1 to SEQ ID NO:8.
[0045] In certain embodiments, each bispecific antibody can be conjugated to two or more different biomolecules on the same target surface.
[0046] In certain embodiments, each bispecific antibody can be conjugated to two or more different molecules on the surface of different targets. In these embodiments, when different targets are close, these targets can be connected to each other through the conjugated bispecific antibodies.
[0047] In certain embodiments, the targets of the bispecific antibody include, but are not limited to, non-living substances and living substances, such as NK cells, T cells, macrophages, dendritic cells, erythrocytes, B cells, cancer cells, viruses, bacteria, fungi, yeasts, and parasites.
[0048] In certain embodiments, the one or more biomolecules or biomarkers that the biomarker binding peptide can target include, but are not limited to, epidermal growth factor receptor (EGFR), epithelial cell adhesion molecule (EpCAM), programmed death ligand 1 (PD-L1), integrin, human epidermal growth factor receptor 2 (HER-2), and phosphatidylinositol proteoglycan-3.
[0049] In certain embodiments, the one or more biomarker binding peptides can be linear peptides, cyclic peptides, stapled peptides, branched peptides, dendritic peptides, or scaffold peptides.
[0050] In certain embodiments, the linear biomarker binding peptide can be conjugated to the N-terminus, C-terminus, disulfide bond, or any amino acid side chain of the monoclonal antibody.
[0051] In certain embodiments, the cyclic biomarker binding peptide is formed by cyclizing the biomarker binding peptide through a chemical bond between the N-terminus and the C-terminus, between one side chain and another side chain, or between one of the N-terminus and the C-terminus and a side chain, thereby forming a cyclic peptide backbone.
[0052] In certain embodiments, the chemical bond between the N-terminus and the C-terminus, between one side chain and another side chain, or between one of the N-terminus and the C-terminus and the side chain used to form the cyclic peptide backbone can be a covalent bond, a supramolecular interaction, or a disulfide bond.
[0053] In certain embodiments, the cyclic peptide backbone of the cyclic biomarker binding peptide is chemically conjugated to a region of a monoclonal antibody via a chemical linker, while at least one sequence of one or more biological molecules capable of targeting a target is distal to the region of the monoclonal antibody to which the cyclic peptide backbone is chemically conjugated.
[0054] In certain embodiments, the chemical linker is a bifunctional linker having a first functional domain capable of cyclizing a biomarker binding peptide and a second functional domain that chemically conjugates to a region of a monoclonal antibody.
[0055] In one embodiment, the biomarker binding peptide is cyclized by one of the functional domains of the bifunctional linker, while the other functional domain of the bifunctional linker will form a chemical conjugate with a region of the monoclonal antibody.
[0056] The third aspect of the present invention provides a method for treating a disease in a subject in need of immunotherapy, wherein the method comprises: administering to the subject a composition comprising a therapeutically effective amount of the bispecific antibody described herein; or the third aspect of the present invention provides the use of a bispecific antibody in the preparation of a composition for use as an immunotherapy to treat a disease in the subject.
[0057] In certain embodiments, the composition is capable of triggering antibody-dependent cellular phagocytosis (ADCP).
[0058] In certain embodiments, each bispecific antibody has one or more chemically conjugated biomarker binding peptides, each biomarker binding peptide comprising a sequence that can be conjugated to one or more corresponding biomolecules of a target cell, and the bispecific antibody is capable of targeting receptors on a subject's macrophages to trigger macrophage-mediated phagocytosis of the target cells.
[0059] In certain embodiments, target cells include, but are not limited to, cancer cells or tumor initiating cells.
[0060] In certain embodiments, a receptor on a macrophage that was initially inactivated by a cancer cell antigen is activated by administering to a subject a composition comprising a therapeutically effective amount of a bispecific antibody.
[0061] In certain embodiments, the one or more biomolecules or biomarkers that the biomarker binding peptide can target include, but are not limited to, epidermal growth factor receptor (EGFR), epithelial cell adhesion molecule (EpCAM), programmed death ligand 1 (PD-L1), integrin, human epidermal growth factor receptor 2 (HER-2), and phosphatidylinositol proteoglycan-3.
[0062] In certain embodiments, the composition can be administered by intravenous injection, intratumoral injection, subcutaneous injection, intraperitoneal injection, or intramuscular injection.
[0063] In certain embodiments, the composition may be administered with, before, or after other cancer therapies including, but not limited to, radiation therapy and chemotherapy.
[0064] In certain embodiments, the disease to be treated includes cancer, such as head and neck cancer, ovarian cancer, cervical cancer, bladder cancer, esophageal cancer, gastric cancer, breast cancer, endometrial cancer, colorectal cancer, lung cancer, pancreatic cancer, skin cancer, and non-small cell lung cancer.
[0065] Other aspects of the present invention include a method for preparing a drug or pharmaceutical composition for immunotherapy or treatment of pathogenic infection or disease using the bispecific antibodies described herein. Depending on the properties of the target or biomolecule to be conjugated, the conformation of one or more biomarker binding peptides and / or the conjugation strategy between the immunoglobulin and the biomarker binding peptide may be different. The present invention also includes a kit for targeting certain cell types, tissues or biomolecules, the kit comprising the bispecific antibodies described herein, which are chemically conjugated with one or more biomarker binding peptides, which have sequences that can be specifically conjugated with one or more biomarkers of certain cell types, tissues or biomolecules. In certain embodiments, when the bispecific antibody is specifically conjugated with one or more corresponding biomarkers expressed by the target cell type, tissue or biomolecule to activate the indicator, the bispecific antibody can be further conjugated with the indicator to determine whether the target cell type, tissue or biomolecule is present in the sample in vitro or in vivo. According to certain embodiments, the indicator of the kit includes but is not limited to fluorescent dyes and colorimetric dyes. The kit or bispecific antibody according to certain embodiments is capable of detecting in vitro and in vivo whether there is one or more corresponding cell types or tissues that overexpress a certain or certain biomarkers. The signal generated by the corresponding indicator associated with the conjugation between the bispecific antibody and the target cell type / tissue can also be used to quantify the cell viability of the target cell / tissue for certain treatment regimens, thereby evaluating its efficacy on certain cell types / tissues. The kit can also be used for disease prognosis in the following manner: indicating the number or degree of abnormal cells or tissues that overexpress a certain or certain biomarker (detectable by bispecific antibodies and indicators) in the sample, thereby indicating whether there is a disease or whether it may develop to certain stages of the disease.
[0066] The present invention content introduces some concepts in a simplified form, and these concepts will be further described in the following detailed description. The present invention content is not intended to identify the key features or essential features of the claimed subject matter, nor is it intended to be used to assist in determining the scope of the claimed subject matter. As described in the following detailed description, other aspects of the present invention are disclosed. BRIEF DESCRIPTION OF THE DRAWINGS
[0067] The accompanying drawings (in which the same reference numerals represent the same or functionally similar elements) include drawings of certain embodiments to further illustrate and clarify the above and other aspects, advantages and features of the present invention. It should be appreciated that these drawings depict embodiments of the present invention and are not intended to limit the scope thereof. By using the accompanying drawings, the present invention will be described and illustrated in more detail, wherein:
[0068] Figure 1The structures of different conventional monoclonal and bispecific antibodies (left two panels) and the peptide bispecific antibody (pBsAb) of the present invention (right panel) are schematically shown.
[0069] Figure 2A The general synthetic scheme for one-pot peptide cyclization and antibody conjugation according to certain embodiments of the present invention is schematically shown.
[0070] Figure 2B A more detailed synthetic scheme for one-pot peptide cyclization and antibody conjugation according to certain embodiments of the present invention is schematically shown.
[0071] Figure 2C Schematically illustrated is an embodiment of the pBsAb of the present invention, which is derived from anti-signal regulatory protein α (SIRPα) conjugated to an o-phthalaldehyde-functionalized cyclic epidermal growth factor receptor (EGFR) targeting peptide (hereinafter referred to as "cEBP-OPA") and how it is associated with the activation of macrophage-mediated cancer cell phagocytosis.
[0072] Figure 3 Confocal images of HT29 and HeLa cells after incubation for 1 hour with native (non-specific) IgG (20 nM) (left) and cyclic peptide-modified IgG (cEBP-IgG) (20 nM) according to certain embodiments of the present invention are shown.
[0073] Figure 4 Shown are the results of ELISA binding assays of pBsAbs of the invention against (A) EGFR and (B) SIRP-α. Data are presented as mean ± standard error (SEM) of three independent experiments, each performed three times.
[0074] Figure 5 The results of cell binding assays for anti-SIRP mAbs and pBsAbs of the present invention are shown for RAW264.7, HT29, A549 and HeLa cells: (A) confocal microscopy images; (B) flow cytometry data after 30 minutes of treatment with anti-SIRP mAbs and pBsAbs of the present invention. Data are expressed as mean ± SEM of three independent experiments.
[0075] Fig. 6A Confocal microscopy images of co-culture binding experiments are shown. RAW264.7 macrophages were incubated with EGFR overexpressing cells HT29 (upper panel) and EGFR low-expressing cells HeLa (lower panel). The data show that in the presence of pBsAb (compared to HeLa), a greater number of cell clusters (white circles) were formed between HT29 and RAW264.7.
[0076] Figure 6B Shown are the results of a macrophage-cancer cell binding assay performed on unlabeled A549 EGFR-overexpressing cells in the presence of anti-SIRP mAbs and pBsAbs of the invention compared to a control (without any antibody): confocal microscopy images (upper panels) and a graph showing the number of macrophages bound to the A549 surface in the different treatment groups (lower panels).
[0077] Figure 7A-7B Results of antibody-dependent cellular phagocytosis (ADCP) assays in different cell lines are shown, where: Fig. 7A shows confocal microscopy images of RAW264.7 macrophages (CFSE) co-cultured with A549, HT29 and HeLa cells (CellTracker Red) treated with pBsAb of the present invention according to certain embodiments and anti-SIRP-α monoclonal antibody (20 nM) for 24 hours (arrows indicate phagocytic macrophages); Figure 7B Flow cytometry quadrant analysis of RAW264.7 macrophages (CFSE) co-cultured with A549, HT29 and HeLa cells (CellTrackerRed) treated with pBsAb (20 nM) or anti-SIRP-α mAb (20 nM) or without any treatment control for 2 hours is shown. Grey squares show the percentage of phagocytic macrophages under different conditions.
[0078] Figure 8 Shown is a quantitative analysis of ADCP assay performed on RAW264.7 macrophages for EGFR overexpressing cells (A549 and HT29) and EGFR low expressing cells (HeLa and HepG2) treated with different concentrations of the pBsAb of the present invention according to certain embodiments and anti-SIRP-α mAb.
[0079] Fig.9A Shown are confocal Z-stack maximum projection microscopy images of HT29 cancer cell spheroids co-cultured with RAW264.7 macrophages (second column from the left) treated with pBsAb of the present invention according to certain embodiments and anti-SIRP-α mAb (50 nM) for 24 hours (dead cells were stained with PI (second column from the right)).
[0080] Fig. 9B Shown are confocal microscopy images of 3D spheroids of green fluorescently labeled macrophage-infiltrated HT29 cells in the presence of a pBsAb of the invention, according to certain embodiments.
[0081] Fig.10 It shows that Figure 2BShown are (a) HPLC chromatogram and (b) MALDI-TOF mass spectrum of cEBP-OPA.
[0082] Fig.11 It shows that Figure 2B MALDI-TOF mass spectrum of the EBP peptide shown.
[0083] Those skilled in the art will appreciate that elements in the figures are illustrated for simplicity and clarity and have not necessarily been drawn to scale. DETAILED DESCRIPTION
[0084] It is obvious to those skilled in the art that modifications (including additions and / or substitutions) may be made without departing from the scope and spirit of the invention. Specific details may be omitted to avoid obscuring the invention; however, this disclosure is written to enable those skilled in the art to practice the teachings herein without undue experimentation.
[0085] Provided herein is a novel bispecific antibody, designated as peptide bispecific antibody (abbreviated as "pBsAb") ( Figure 1 ). It utilizes a one-pot peptide cyclization and protein conjugation reaction strategy to efficiently cyclize and conjugate tumor-targeting peptides to monoclonal antibodies to produce bispecifics. The key molecule in this reaction is a bifunctional linker containing a dibromomethylbenzene unit for peptide cyclization and an o-phthalaldehyde unit for protein conjugation. In certain embodiments, pBsAb is provided by conjugating an EGFR-targeted cyclic peptide to an anti-SIRP-α monoclonal antibody to form an EGFR x SIRP-α pBsAb.
[0086] pBsAb according to certain embodiments is prepared starting from a monoclonal antibody, a bifunctional linker and a linear tumor targeting peptide. The bifunctional linker is provided to generate a serum-stable cyclic peptide-dye conjugate by a one-pot peptide cyclization and dye conjugation reaction. One end of the bifunctional linker contains a dibromomethylbenzene (DBMB) unit for complete deprotection of the peptide ( Figure 2B The site-selective alkylation of the sulfhydryl (SH) side chains of the two cysteine residues of the amino acid sequence (shown in (ii)) to form a monocyclic structure. The other end is bound to the o-phthalaldehyde moiety for protein conjugation via the o-phthalaldehyde-amine capture (PAC) reaction. These two reactions can be performed in a one-pot orthogonal manner.
[0087] ( Figure 2A-2B ).
[0088] A proof-of-concept experiment was performed by conjugating the EGFR-targeting cyclic peptide to a nonspecific IgG that does not have any selectivity for tumor cells but has the ability to target macrophages. Figure 2C A schematic diagram is provided in the figure showing how to Figure 2A-2B The EGFR×SIRP-αpBsAb synthesized in a one-pot orthogonal manner as described in was used to target certain cancer cell types and initiate macrophage-mediated phagocytosis of these cancer cell types. In this experiment, EGFR-positive HT29 colorectal cancer was selected as the target cell, and EGFR-low-expressing HeLa cervical adenocarcinoma was selected as the control cell line. To this end, a bifunctional linker was first synthesized. Briefly, methyl-ester acetal-protected o-phthalaldehyde 1 prepared according to previous literature was reduced with LiAlH4 to give hydroxyl group 2. Then, in the presence of NaH, 2 reacted with 1,3,5-tris(bromomethyl)-benzene via nucleophilic monosubstituted to give linker 3. The details of the synthesis of this bifunctional linker can be found in Scheme S1 in the Examples section below.
[0089] To prepare the o-phthalaldehyde functionalized cyclic EBP, compound 3 was treated with trifluoroacetic acid (TFA) to achieve in situ deprotection. It was then reacted with a linear peptide (EBP) (1:1 molar ratio (1 mM) with a mixture of N,N-dimethylformamide (DMF) and borate buffer (pH 9.0) (100 μL, 1:1 v / v) at room temperature for 2 hours to obtain EBP-OPA. RP-HPLC and mass spectrometry were used to characterize the cyclization process ( Figure 10-11 Without further purification, the cyclized product EBP-OPA was mixed with a nonspecific human IgG solution in phosphate buffered saline (PBS) (pH=7.4) (1 mL) at a peptide-protein molar ratio of 10:1, and the excess peptide was removed by dialysis. The data showed that the peptide-modified IgG was able to bind to the surface of HT29 cells, but not to HeLa cells. In contrast, native IgG did not bind to any cell surface ( Figure 3 ). These data demonstrate that additional tumor-targeting functionalities have been successfully incorporated into antibodies following the proposed one-pot synthetic approach.
[0090] Under the condition of credible data, the same method was used to conjugate EGFR binding cyclic peptides to commercial rabbit anti-SIRP-α monoclonal antibodies to form a novel EGFR x SIRP-α pBsAb. In order to optimize pBsAb, it is necessary to determine the optimal ratio of cyclic peptide to antibody to produce the highest binding affinity for SIRP-α and EGFR. To this end, pBsAb (20nM) with different cyclic peptide ratios (1:1, 10:1, 20:1, 50:1 and 100:1) was synthesized, and pBsAb was incubated with SIRP-α (0.5μg / ml) or EGFR (1μg / ml) on an ELISA plate at room temperature for 2 hours. After washing, anti-rabbit-HRP secondary antibody was added and incubated for 1 hour at room temperature in the dark. The absorbance was measured using a microplate reader and the readings were recorded on Figure 4 The results show that pBsAb conjugated with a 100-fold excess of cyclic peptide provides the best binding affinity for EGFR in five different ratios. When the ratio of cyclic peptide to antibody is 50:1, there is no significant change in binding affinity for SIRP-α compared to the natural anti-SIRP-α antibody. Therefore, the results show that the 50:1 cyclic peptide-antibody ratio is an ideal candidate ratio for binding to EGFR and SIRP-α, and this construct was used for subsequent testing.
[0091] After optimizing the EGFR x SIRP-α pBsAb, in vitro binding assays were performed to demonstrate the binding ability of pBsAb against EGFR-positive cell lines and macrophages. Confocal microscopy showed that when PE-labeled pBsAb was incubated with EGFR-overexpressing cell lines A549 and HT29, fluorescence signals were observed on the cell surface. When pBsAb was incubated with SIRP-α-positive RAW264.7 mouse macrophages, strong fluorescence signals were also observed. However, no fluorescence signals were observed when pBsAb was incubated with HeLa cells, which is an EGFR-low-expressing cell line ( Figure 5 A). Flow cytometry was used to further quantify the binding of pBsAb to different cell lines ( Figure 5 B). The results showed that when the anti-SIRP-α natural antibody was compared with the EGFR xSIRP-α pBsAb of the present invention, the binding ability of pBsAb against the EGFR-positive cell line HT29 was very significant, demonstrating its dual specificity against EGFR and SIRP-α at the cellular level.
[0092] Cell culture formation assays showed that when both cells were added together in the same dish, cell clusters were observed to form between macrophages and cancer cells in the presence of pBsAB. Fig. 6A) Cell adhesion assays also demonstrated that the addition of fluorescently labeled macrophages atop seeded A549 cells enhanced the binding between cancer cells and immune cells in the presence of pBsAb. Figure 6B )
[0093] In case of high binding specificity against EGFR and SIRP-α positive cell lines, antibody-dependent cellular phagocytosis (ADCP) activity of macrophages was further tested. To this end, different cell lines were co-cultured in the presence and absence of the proposed pBsAb. Fig. 7A It is shown that in the presence of 20nM pBsAb, the cytoplasm of green-labeled RAW264.7 macrophages has strong red fluorescence derived from EGFR-overexpressing A549 and HT29 cells. The EGFR low-expressing cell HeLa did not show the same phenomenon. This further indicates that phagocytosis occurred and the red-labeled cancer cells were engulfed. On the other hand, when the co-cultured cells were incubated with anti-SIRP-α mAb, phagocytosis occurred to a much lesser extent. This series of imaging data clearly demonstrates that the proposed EGFR x SIRP-α pBsAb enhances antibody-dependent cellular phagocytic activity. The confocal microscopy data were further quantified by flow cytometry and analyzed by quadrant analysis. In short, RAW264.7 was stained with CFSE and HT29 or HeLa was stained with Cell Tracker Red before the assay. Macrophages and cancer cells were then added to a round-bottom 96-well plate at a ratio of approximately 1:1 and incubated for 2 hours at 37°C and 5% CO2 in a full medium culture environment in the presence or absence of 20 nM pBsAb. After incubation, flow cytometry was used to determine the percentage of phagocytosis by RAW264.7 macrophages. From the quadrant analysis, the data clearly showed that compared with cells without pBsAb ( Figure 7B , the following two figures) compared with the presence of pBsAb ( Figure 7B , the percentage of double positive (upper right corner) cells in the two figures above increased significantly. The increase in cells in the double positive area indicates that more macrophages have implemented phagocytic activity. In contrast, no enhancement of phagocytic activity was observed on EGFR low-expressing HeLa cells. Therefore, these quantitative data show the specificity of the bispecific antibodies of the present invention. This also proves that the enhancement of macrophage-mediated phagocytosis is antibody-dependent.
[0094] The ADCP activity of RAW264.7 macrophages against HT29 and A549 cells was determined based on cell viability using the CellTiter-Glo Luminescent Cell Viability Kit (Promega), and the relative antibody-dependent cellular phagocytic activity was calculated as EC 50 .like Figure 8 As shown, different concentrations of pBsAb can enhance the phagocytic activity that produces anti-cancer effects compared to unmodified 50nM anti-SIRP-α mAb. Therefore, it is shown that the pBsAb of the present invention induces a significant enhancement of ADCP against the target EGFR high-expressing cell line compared to the natural anti-SIRP antibody. Compared with the EGFR low-expressing HeLa cell line, pBsAb also significantly enhanced ADCP against the EGFR high-expressing cell line. In general, the one-pot chemical conjugation strategy of the present invention has been shown to convert a single target monoclonal antibody into a bispecific antibody.
[0095] Finally, macrophage infiltration and ADCP antitumor effects in a three-dimensional HT29 spheroid model were demonstrated in the presence of pBsAb or unmodified anti-SIRP-α mAb. The three-dimensional tumor spheroid model is used to mimic the in vivo tumor situation more closely than the monolayer setting. Briefly, HT29 cells (5x10 4 The spheroids were formed by 3 days of culture and incubation with RAW264.7 cells (1×10 3 The spheroids were further co-cultured with pBsAb or anti-SIRP-α mAb (50 nM) in complete cell culture medium at 37°C for 24 h. After 24 h of incubation, the spheroids were also stained with propidium iodide (PI) to detect dead cells. Finally, the spheroids were transferred to confocal microplates for imaging. Fig.9A As shown, the Z-stack maximum projection confocal images clearly show that the number of macrophages in the core of the spheroids treated with pBsAb (fluorescent signals in the second column from the left) is significantly higher than that of the spheroids treated with anti-SIRP-α mAb. In addition, when the spheroids were treated with pBsAb, a higher intensity of red fluorescent PI was observed in the spheroids, including PI in the core of the spheroids (fluorescent signals in the second column from the right). Fig. 9B It is shown that some CFSE-stained macrophages successfully entered the spheroids (indicated by solid arrows).
[0096] In summary, the one-pot chemical conjugation method provided herein successfully converts a monospecific antibody (e.g., a monoclonal antibody) into a novel bispecific antibody (i.e., a peptide bispecific antibody (pBsAb)) with proven bispecificity and enhanced antibody-dependent cellular phagocytosis (ADCP). The EGFRx SIRP-α pBsAb prepared according to certain embodiments has been shown to be able to bind to EGFR-overexpressing cells and SIRP-α of macrophages, thereby connecting together to form a new cell-cell interaction between target cells and macrophages. This design enhances antibody-dependent cellular phagocytosis. The establishment of the platform of the present invention allows for the rapid production of bispecific antibodies for immunotherapy at low cost.
[0097] In certain embodiments, the present invention also includes any structure of peptides, such as but not limited to linear peptides, cyclic peptides, stapled peptides, branched peptides, dendritic peptides, and scaffold peptides.
[0098] In certain embodiments, molecules other than peptides that can target tumors or have tumor targeting capabilities should also be considered as potential candidates for chemical conjugation to antibodies to generate the bispecific antibodies of the present invention.
[0099] It should be understood that the above embodiments and examples are intended to assist in illustrating the present invention, but should not be considered as limiting the scope of the present invention (e.g., limiting certain mechanisms for linking peptides to antibodies). Any chemical reaction known to those of ordinary skill in the relevant art that can link peptides to antibodies without departing from the purpose and spirit of the present invention should also be within the scope of the present invention and used to implement the present invention.
[0100] The following descriptions further characterize the structure, performance and preparation method of the novel bispecific antibody of the present invention as various examples and are supported by corresponding experiments, but the scope of the present invention should not be construed as being limited thereto.
[0101] Example
[0102] (A) General Materials and Characterization Methods:
[0103] N,N-dimethylformamide (DMF), tetrahydrofuran (THF), and CH2Cl2 were dried using the INERT solvent drying system prior to use. Acetonitrile was of HPLC grade. All other solvents were of analytical grade and used without further purification. All reactions were performed under a nitrogen atmosphere and monitored by thin layer chromatography (TLC; Merck pre-coated silica gel 60F254 plates). Chromatographic purification was performed on a silica gel (Macherey-Nagel, 230 to 400 mesh) column with the specified eluent. Compounds 1, 2, cEBP-OPA, and pBsAB were prepared according to literature procedures.
[0104] On a Bruker Avance III 500 spectrometer ( 1 H, 500MHz; 13 C, 125.7 MHz), recorded in deuterated solvents 1 H and 13 C{ 1 H} NMR spectrum. By taking the residual solvent relative to SiMe4 { 1 H, δ = 7.26 (for CDCl3), δ = 3.31 (for CD3OD), δ = 2.50 [for dimethyl sulfoxide (DMSO)-d6]} or solvent [ 13 C, δ = 77.2 (for CDCl3), δ = 49.0 (for CD3OD), δ = 39.5 (for DMSO-d6)] resonance, internal reference spectra. Electrospray ionization (ESI) mass spectra were recorded on a Thermo FinniganMAT 95XL mass spectrometer or a Bruker SolariX 9.4Tesla FTICR mass spectrometer. Matrix-assisted laser desorption / ionization time of flight (MALDI-TOF) mass spectra were recorded on a Bruker Daltonics Autoflex III spectrometer. UV-visible spectra and steady-state fluorescence spectra were obtained on a Shimazu UV-1800 UV-visible spectrophotometer and a Horiba FluoroMax-4 spectrofluorometer, respectively.
[0105] For analytical purposes, the HPLC-MS / MS was performed on an XBridge BEH300 C18 column (5 μm, 4.6 mm × 150 mm) at 1 mL min using a Waters system equipped with a Waters 1525 binary pump and a Waters 2998 photodiode array detector. -1 The separation was performed on a reversed-phase HPLC column (5 μm, 10 mm × 250 mm) at a flow rate of 3 mL min for preparative purposes. -1 Reverse phase HPLC separation was performed at a flow rate of . The solvent used for HPLC analysis was HPLC grade. The conditions for analysis were set as follows: Solvent A was 0.1% trifluoroacetic acid (TFA) in acetonitrile, and Solvent B was 0.1% TFA in deionized water; Gradient: 5% A + 95% B for the first 5 minutes, then changed to 15% A + 85% B after 10 minutes, further changed to 100% A + 0% B after 30 minutes, maintained under this condition for 5 minutes, changed to 0% A + 100% B after 5 minutes, and maintained under this condition for another 5 minutes.
[0106] (B) Preparation of EBP and arginine-glycine-aspartic acid (RGD) peptide :
[0107] The EBP (AcNH-CMYIEALDRYAC-COHN2) peptide (SEQ ID NO: 1) was manually synthesized using a modified 9-fluorenylmethoxycarbonyl (Fmoc) solid phase peptide synthesis protocol with commercially available N-α-Fmoc protected amino acids. RINK amide resin was used as a solid support. The Fmoc protecting group was removed with 20% piperidine in DMF, and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo-[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU) was used as a carboxyl activator. Each coupling was performed at room temperature using an excess of Fmoc protected amino acids (4 equiv.), HATU (4 equiv.), and N,N-diisopropylethylamine (DIPEA) (8 equiv.). For N-terminal acetylation, a mixture of CH2Cl2 / pyridine / acetic anhydride (2 / 1 / 1 v / v / v) was added, and the mixture was stirred at room temperature for 30 minutes. After washing with DMF and CH2Cl2, the resin is treated with a solution containing 95% TFA, 2.5% triisopropylsilane (TIS) and 2.5% CH2Cl2 for 1 hour to cut the peptide from the resin and remove the protecting groups. The resin is removed by filtration, and the filtrate is precipitated by adding ether. After centrifugation, the supernatant is removed. The solid is redissolved in DMSO and the solution is precipitated again with ether. The precipitated peptide is freeze-dried to obtain a crude peptide, which is purified by reverse phase HPLC and then freeze-dried. Alternatively, the RGD peptide can be used to replace the EBP peptide or used in combination with it. The RGD peptide can be synthesized in situ according to standard protocols or obtained from the corresponding manufacturer (e.g., SIGMA Cas No.: 99896-85-2). For EBP: HRMS (MALDI-TOF): C 64 H 99 N 16 O 19 S3[M+H] + The calculated m / z value is 1491.6429; the result is 1491.6347. For RGD: HRMS (MALDI-TOF) C 29 H 45 N 10 O9S2[M+H] + The calculated value of m / z is 741.2807; the result is 741.2610.
[0108] Scheme S1. Preparation of o-phthalaldehyde:
[0109]
[0110] (C) Preparation of Compound 2 :
[0111]
[0112] The o-phthalaldehyde 1 (0.5 g, 1.9 mmol) protected by methyl ester acetal was treated with a solution of LiAlH4 (75 mg, 2.0 mmol) in THF (20 mL) at 0 ° C. The reaction mixture was stirred for 3 hours and then quenched by adding methanol. The mixture was filtered through diatomaceous earth and the filtrate was evaporated under reduced pressure. Water (20 mL) was then added to the residue and the crude product was extracted with ethyl acetate (20 mL × 3). The combined organic phase was dried over anhydrous Na2SO4 and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica gel using hexane / ethyl acetate (1:1 v / v) as an eluent to obtain 2 (0.42 g, 94%). 1 H NMR (400MHz, CDCl3): δ7.27-7.32(m,2H,ArH),7.23(s,1H,ArH),6.29-6.31(m,1H,CH),6.04(d,J=8.4Hz,1H,CH),3.67(q,J= 5.6Hz,2H,OCH2),3.42-3.46(m,6H,CH3),2.77(t,J=7.6Hz,2H,CH2),1.89(quintet,J=6.4Hz,2H,CH2),1.31(t,J=4.8Hz,1H,OH). 13 C{ 1 H}NMR (100.6MHz, CDCl3): δ144.0,143.9,138.8,138.7,136.1,136.0,130.2, 130.1,122.8,122.7,106.5,105.4,61.9,54.3,54.1,34.1,31.9.HRMS(ESI):C 13 H 18 NaO4[M+Na] + The calculated value of m / z is 261.1097; the result is 261.1096.
[0113] (D) Preparation of compound 3:
[0114]
[0115] A mixture of 2 (0.4 g, 1.7 mmol) and Et3N (0.5 mL, 3.6 mmol) in CH2Cl2 (20 mL) was stirred at 0 °C. To the reaction mixture was then slowly added p-toluenesulfonyl chloride (0.4 g, 2.1 mmol). After stirring overnight, the mixture was evaporated under reduced pressure. Water (20 mL) was then added to the residue, and the crude product was extracted with ethyl acetate (20 mL × 3). The combined organic phase was dried with anhydrous Na2SO4, and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica gel using hexane / ethyl acetate (3:1 v / v) as an eluent to obtain 3 (0.56 g, 85%). 1 H NMR (400MHz, CDCl3): δ7.79(d,J=8.4Hz,2H,ArH),7.35(d,J=8.4Hz,2H,ArH),7.28(s,1H,ArH),7.13-7.15(m,2H,ArH),6.25-6.28(m,1H,CH),6.01( d,J=13.6Hz,1H,CH),4.02(t,J=6.4Hz,2H,OCH2),3.42-3.44(m,6H,CH3),2.71(t,J=7.6Hz,2H,CH2),2.46(s,3H,CH3),1.96(quintet,J=7.2Hz,2H,CH2). 13 C{ 1 H}NMR (100.6MHz, CDCl3): δ144.9,142.7,142.5,139.1,139.0,136.7,136.6,133.2,130.3,130.2 ,130.0,128.0,123.1,122.8,106.6,105.5,69.5,54.5,54.4,54.3,31.5,30.6,21.8.HRMS(ESI):C 20 H 24 NaO6S[M+Na] + The calculated value of m / z is 415.1186; the result is 415.1186.
[0116] (E) Preparation of Compound 4 :
[0117]
[0118] A mixture of 1,3,5-tri(bromomethyl)benzene (0.28 g, 0.8 mmol) and sodium hydride (60% suspended in mineral oil, 25.2 mg, 0.6 mmol) in THF (5 mL) was stirred at 0°C. A solution of compound 3 (75.0 mg, 0.3 mmol) in THF (5 mL) was added dropwise to the suspension. The reaction mixture was stirred continuously at 0°C for 1 hour and then slowly warmed to room temperature overnight. The solvent was evaporated under reduced pressure. Water (20 mL) was then added to the residue, and the crude product was extracted with CH2Cl2 (20 mL×3). The combined organic phase was dried over anhydrous Na2SO4. After evaporating the solvent under reduced pressure, the crude product was purified by column chromatography on silica gel using hexane / ethyl acetate (3:1 v / v) as an eluent to obtain 4 (56.0 mg, 35%). 1 H NMR (400MHz, CDCl3): δ7.22-7.34(m,6H,ArH),6.29-6.30(m,1H,CH),6.04(d,J=6.8Hz,1H,CH),4.48(s,6H,C H2),3.49(t,J=6.4Hz,2H,OCH2),3.43-3.45(m,6H,CH3),2.78(t,J=7.6Hz,2H,CH2),1.92-1.99(m,2H,CH2). 13 C{ 1 H}NMR (125.8MHz, CDCl3): δ144.0,143.9,140.1,138.9,138.8,138.6,136.2,136.1,130.3,130.2,128.8,12 8.1,122.9,122.8,122.8,122.7,106.6,105.5,72.2,69.7,54.3,54.2,32.8,32.3,31.3,31.0.HRMS(ESI):C 22 H 26 Br2NaO4[M+Na] + The calculated value of m / z is 537.0071; the result is 537.0081.
[0119] (F) Preparation of cEBP-OPA :
[0120]
[0121] Compound 4 was treated with a mixture of TFA and water (1:1 v / v) at room temperature for 30 minutes. After in situ deprotection with o-phthalaldehyde, the intermediate was treated with a solution of EBP (1 mM) in borate buffer (pH 8.5) at room temperature for 1 hour. Based on HPLC analysis, the conversion rates of cEBP-OPA were 92% and 89%, respectively. For cEBP-OPA: HRMS (MALDI-TOF): C 84 H 117 N 16 O 22 S3[M+H] + The calculated value of m / z is 1797.7685; the result is 1797.7608.
[0122] (G) Preparation of Cyclic Peptide-Antibody Conjugates :
[0123] The monoclonal antibody was first dissolved in phosphate buffered saline (PBS) (pH 7.4) to obtain a 5 μM stock solution. Then cEBP-OPA was added to the PBS solution of the protein solution at a molar ratio of 20:1. The mixture was stirred at room temperature for 30 minutes and then filtered through a molecular membrane filter (molecular weight cutoff of 3 kDa) to remove excess unconjugated peptide to form cEBPxSIRP-alpha pBsAb. The pBsAb was retained on the molecular membrane filter and redissolved in PBS for later use.
[0124] (H) ELISA analysis of pBsAb binding to EGFR and SIRP-α :
[0125] NUNC Maxisorp plates (ThermoScientific) were coated with equimolar EGFR or SIRP-α proteins overnight at 4°C. The plates were washed three times with PBS containing 0.05% Tween-20 and blocked with 2% bovine serum albumin in PBS (containing 0.1% Tween-20) for 2 hours at room temperature. 5-fold serial dilutions of pBsAb starting at 80nM were added and the plates were incubated for 2 hours at room temperature. The plates were washed three times and incubated with horseradish peroxidase (HRP)-conjugated goat anti-rabbit secondary antibody (ITK SouthernBiotech) diluted 1:2000 in blocking buffer for 1 hour at room temperature. 100ul of TMB substrate (Biogene, China) was added to each well within 6 minutes. HRP activity was measured at 450nm by ELISA microplate reader. Nonlinear regression analysis of binding curves was performed using GraphPad Prism to calculate the half-maximal effective concentration (EC 50 ) combined value.
[0126] (I) Cell lines and culture conditions :
[0127] All cell lines were maintained in Dulbecco's Modified Eagle Medium (DMEM) (ThermoFisher Scientific, cat. no. 12100-046) supplemented with fetal bovine serum (FBS) (10%) and penicillin-streptomycin (100 units mL each). -1 and 100 μg mL -1 HT29 human colorectal adenocarcinoma cells (ATCC, no. HTB-38), HeLa human cervical carcinoma cells (ATCC, no. CCL-2), MDA-MB-231 human breast cancer cells (ATCC, no. HTB-26), and MCF-7 human breast cancer cells (ATCC, no. HTB-22) were maintained in Roswell Park Memorial Institute (RPMI) 1640 medium (Invitrogen, cat. no. 23400-021) supplemented with FBS (10%) and penicillin-streptomycin (100 units mL each). -1 and 100 μg mL -1 U87-MG human glioblastoma cells (ATCC, no. HTB-14) were maintained in minimum essential medium (MEM) (Sigma-Aldrich, no. M5650) supplemented with FBS (10%) and penicillin-streptomycin (100 units mL -1 and 100 μg mL -1 All cells were cultured at 37°C in a humidified 5% CO2 atmosphere.
[0128] (J) Confocal fluorescence microscopy studies :
[0129] Approximately 2 × 10 5 Cells were seeded on glass bottom confocal culture dishes and incubated overnight at 37°C in a humidified 5% CO2 atmosphere. To study cell binding, cells were incubated with phycoerythrin-labeled pBsAb in serum-free medium at 37°C for 30 minutes after rinsing with PBS. Cells were rinsed twice with PBS and then incubated for another 3 hours in serum-free medium. The solution was then removed, cells were rinsed twice with PBS, and then examined with a Leica TCS SP8 high-speed confocal microscope equipped with a solid-state laser. pBsAb was excited at 488nm and its fluorescence was monitored at 500-530nm. Images were digitized and analyzed using Leica Application Suite X software.
[0130] (K) Flow cytometry analysis :
[0131] Approximately 2 × 10 cells / well were added to DMEM, RPMI 1640 medium or MEM (2 mL). 5 Cells were seeded on 6-well plates and incubated overnight at 37°C in a humidified 5% CO2 atmosphere. After rinsing the cells with PBS, the cells were incubated with different concentrations of pBsAb or natural mAb in serum-free medium at 37°C for 1 hour. The cells were then rinsed twice with PBS and harvested for 5 minutes with 0.25% trypsin-ethylenediaminetetraacetic acid (Invitrogen, 0.2 mL). The activity of trypsin was quenched with serum-containing culture medium (0.5 mL), and the mixture was centrifuged at 1500 rpm for 3 minutes at room temperature. The precipitate was washed with PBS (1.0 mL) and then centrifuged. The cells were then suspended in PBS (1.0 mL) and the intracellular fluorescence intensity was measured using a BDFACSVerse flow cytometer (Becton Dickinson), with 10 counts in each sample. 4 Cells were collected and analyzed using BD FACSuite. All experiments were performed three times.
[0132] (L) Double staining phagocytosis assay :
[0133] RAW264.7 macrophages were harvested by washing adherent differentiated cells in 10 mL of cold PBS, incubating for 10 min, and then gently scraping off. Macrophages were counted using an automated cell counter that also counted 3x10 6 The viability of (Vi-CELL XR Cell Viability Analyzer, Beckman Coulter, Brea, CA). 10 μM CFSE (Thermo Fisher Scientific, Eugene OR) was loaded into macrophages according to the manufacturer's instructions. Other cells, HT29 or HeLa, were stained by Cell Tracker Red according to the manufacturer's instructions. Then, the two cells were mixed in a round-bottom plate at 37°C for 2 hours in the presence of 20 nM pBsAb. After incubation, the cells were fixed with 4% paraformaldehyde and washed three times with PBS. The intracellular fluorescence intensity was measured using a BD FACSVerse flow cytometer (Becton Dickinson), and 10 cells were counted in each sample. 4 Cells were collected and analyzed using BD FACSuite. All experiments were performed three times.
[0134] It will be apparent to those skilled in the art that modifications (including additions and / or substitutions) may be made without departing from the scope and spirit of the invention. Specific details may be omitted to avoid obscurity of the invention; however, the disclosure is written to enable those skilled in the art to practice the teachings herein without excessive experimentation. For example, the biomarker binding peptides of the present invention are not limited to the EBP peptides for targeting EGFR described in section (B) of the Examples section, but also include any one or more possible peptides conjugated to immunoglobulins or fragments thereof to simultaneously target multiple biomolecules. Potential candidates should also include, but are not limited to, peptides according to any amino acid sequence of SEQ ID Nos: 2-8, which target EpCAM, PD-L1, integrin, HER2, and GPC3, respectively.
[0135] Although the invention has been described in terms of certain embodiments, other embodiments that would be apparent to one of ordinary skill in the art are also within the scope of the invention.
[0136] Industrial Applicability
[0137] The proposed bispecific antibodies are not only potential therapeutic agents for immunotherapy of various cancers or tumors, the one-pot chemical method proposed in the present disclosure is capable of conjugating tumor-targeting molecules to various forms of immunoglobulins to produce bispecific antibodies, and the one-pot chemical method has the potential to be applied to the development of next-generation immunotherapy, drugs for treating different pathogenic infections or diseases, and medical / clinical diagnostic tools.
[0138] Some advantages of the present disclosure include:
[0139] -Chemical methods for producing bispecific antibodies are generally cheaper and more efficient;
[0140] -By using conjugation chemistry to conjugate tumor targeting peptides to antibodies, dual
[0141] flexibility in specificity;
[0142] - Allows the construction and modulation of the binding and affinity of two targets on one bispecific antibody; and
[0143] As a novel platform technology, it can generate unlimited combinations of bispecific antibodies against two different targets.
Claims
1. A bispecific antibody comprising an immunoglobulin or any fragment thereof chemically or enzymatically conjugated to one or more biomarker binding peptides, wherein the biomarker binding peptides are capable of simultaneously conjugating to multiple biomolecules on one or more targets.
2. The bispecific antibody of claim 1, wherein the immunoglobulin or any fragment thereof is a natural, denatured or synthetic immunoglobulin, including IgG, IgA, IgM, nanobodies, antigen binding fragment regions (Fab), single chain variable fragments (scFv) or peptibodies. The bispecific antibody according to claim 1 , wherein the immunoglobulin is a monoclonal antibody.
4. The bispecific antibody according to claim 3, wherein the monoclonal antibody is an IgG antibody of any specificity from human or any other animal origin.
5. The bispecific antibody of claim 3, wherein the one or more biomarker binding peptides comprise 1 to 100 biomarker binding peptides per monoclonal antibody.
6. The bispecific antibody according to claim 1, wherein each of the biomarker-binding peptides comprises at least one sequence capable of simultaneously targeting at least two biological molecules on the same or different targets, wherein the biological molecules include proteins, peptides, cell surfaces, organelles and / or any soluble substances of the same or different targets.
7. The bispecific antibody of claim 6, wherein the biomarker-binding peptide is capable of targeting biological molecules including epidermal growth factor receptor (EGFR), epithelial cell adhesion molecule (EpCAM), programmed death-ligand 1 (PD-L1), integrin, human epidermal growth factor receptor 2 (HER-2) and glypican-3 (GPC3).
8. The bispecific antibody of claim 1, wherein when two or more different targets are sufficiently close, the two or more different targets are linked together by the conjugated bispecific antibody.
9. The bispecific antibody according to claim 1, wherein the targets of the bispecific antibody include non-living substances and living substances, including NK cells, T cells, macrophages, dendritic cells, erythrocytes, B cells, cancer cells, viruses, bacteria, fungi, yeasts and parasites.
10. The bispecific antibody of claim 1, wherein the one or more biomarker binding peptides are linear peptides, cyclic peptides, stapled peptides, branched peptides, dendritic peptides, or scaffold peptides.
11. The bispecific antibody of claim 10, wherein the linear biomarker binding peptide is conjugated to the N-terminus, the C-terminus, a disulfide bond or any amino acid side chain of the immunoglobulin, wherein the immunoglobulin is a monoclonal antibody.
12. The bispecific antibody according to claim 10, wherein the cyclic biomarker binding peptide is formed by cyclizing the biomarker binding peptide through a chemical bond between the N-terminus and the C-terminus, between one side chain and another side chain, or between one of the N-terminus and the C-terminus and a side chain, thereby forming a cyclic peptide backbone.
13. The bispecific antibody according to claim 12, wherein the chemical bond between the N-terminus and the C-terminus, between a side chain and another chain, or between one of the N-terminus and the C-terminus and the side chain used to form the cyclic peptide backbone is a covalent bond, a supramolecular interaction, or a disulfide bond.
14. The bispecific antibody according to claim 12, wherein the cyclic peptide backbone of the cyclic biomarker binding peptide is chemically conjugated to a region of the monoclonal antibody by chemical conjugation, and at least one sequence of the one or more biological molecules capable of targeting the target is away from the region of the monoclonal antibody that is chemically conjugated to the cyclic peptide backbone.
15. The bispecific antibody of claim 14, wherein the chemical conjugation is performed via a bifunctional linker having a first functional domain capable of cyclizing the biomarker binding peptide and a second functional domain chemically conjugated to the region of the monoclonal antibody.
16. The bispecific antibody according to claim 15, wherein the bifunctional linker is selected from an o-phthalaldehyde linker, and the linear biomarker binding peptide is cyclized by one of the functional domains of the o-phthalaldehyde linker through site-specific dialkylation of the thiol side chains of two cysteine residues in the biomarker binding peptide, while the other functional domain of the o-phthalaldehyde linker forms the chemical conjugation with the region of the monoclonal antibody.
17. A method for preparing a bispecific antibody chemically conjugated to one or more biomarker binding peptides according to any one of the above claims, the method include: Providing immunoglobulin or any fragment thereof; providing one or more biomarker binding peptides, each biomarker binding peptide comprising a sequence of one or more biomolecules capable of targeting a target; and The one or more biomarker binding peptides are conjugated to a region of the immunoglobulin or any fragment thereof by chemical or enzymatic reaction.
18. The method of claim 17, wherein the immunoglobulin or any fragment thereof comprises IgG, IgA, IgM, nanobody, Fab, scFv or peptibody.
19. The method of claim 17, wherein the immunoglobulin is selected from a monoclonal antibody.
20. The method according to claim 19, wherein the monoclonal antibody is an IgG antibody of any specificity from human or any other animal origin.
21. The method of claim 19, wherein the one or more biomarker binding peptides comprise 1 to 100 biomarker binding peptides per monoclonal antibody.
22. The method of claim 17, wherein the one or more biomarker binding peptides are linear peptides, cyclic peptides, stapled peptides, branched peptides, dendritic peptides, or scaffold peptides.
23. The method of claim 22, wherein the linear biomarker binding peptide is conjugated to the N-terminus, C-terminus, disulfide bond or any amino acid side chain of the immunoglobulin, wherein the immunoglobulin is a monoclonal antibody.
24. The method of claim 22, wherein the cyclic biomarker binding peptide is formed by cyclizing the biomarker binding peptide through a chemical bond between the N-terminus and the C-terminus, between one side chain and another side chain, or between one of the N-terminus and the C-terminus and a side chain, thereby forming a cyclic peptide backbone.
25. The method according to claim 24, wherein the chemical bond between the N-terminus and the C-terminus, between one side chain and another side chain, or between one of the N-terminus and the C-terminus and a side chain used to form the cyclic peptide backbone is a covalent bond, a supramolecular interaction, or a disulfide bond.
26. The method of claim 25, wherein the cyclic peptide backbone of the cyclic biomarker binding peptide is chemically conjugated to a region of a monoclonal antibody via a chemical linker, and at least one sequence of the one or more biological molecules capable of targeting the target is distal to the region of the monoclonal antibody to which the cyclic peptide backbone is chemically conjugated.
27. The method of claim 26, wherein the chemical linker is a bifunctional linker having a first functional domain capable of cyclizing the biomarker binding peptide and a second functional domain chemically conjugated to the region of the monoclonal antibody.
28. The method of claim 27, wherein a linear biomarker binding peptide is cyclized by one of the functional domains of the bifunctional linker, and the other functional domain of the bifunctional linker forms the chemical conjugation with the region of the monoclonal antibody.
29. The method of claim 17, wherein the one or more biomolecules of the target include epidermal growth factor receptor (EGFR), epithelial cell adhesion molecule (EpCAM), programmed death ligand 1 (PD-L1), integrin, human epidermal growth factor receptor 2 (HER-2), and glypican-3 (GPC3).
30. Use of the bispecific antibody according to any one of claims 1 to 16 in the preparation of a composition for treating a disease in a subject in need of immunotherapy, the composition comprising a therapeutically effective amount of the bispecific antibody.
31. The use according to claim 30, wherein the composition is capable of triggering antibody-dependent cellular phagocytosis (ADCP).
32. The use according to claim 30, wherein each of the bispecific antibodies has one or more chemically conjugated biomarker binding peptides, each biomarker binding peptide comprising a sequence that can be conjugated to one or more corresponding biomolecules of a target cell or tissue, and the bispecific antibody can target receptors on a subject's macrophages to trigger macrophage-mediated phagocytosis of the target cell or tissue.
33. The use according to claim 32, wherein the target cell comprises a cancer cell or a tumor initiating cell.
34. The use of claim 33, wherein after administering the composition to the subject, receptors on macrophages that were initially inactivated by antigens of the cancer cells or tumor initiating cells are activated by the composition comprising a therapeutically effective amount of the bispecific antibody.
35. The use according to claim 34, wherein the composition is administered by intravenous injection, intratumoral injection or intramuscular injection.
36. The use according to claim 34, wherein the composition is administered together with other cancer therapies including radiation therapy and chemotherapy or before or after the cancer therapy.
37. The use according to claim 30, wherein the disease comprises cancer, including head and neck cancer, ovarian cancer, cervical cancer, bladder cancer, esophageal cancer, gastric cancer, breast cancer, endometrial cancer, colorectal cancer, lung cancer, pancreatic cancer, skin cancer and non-small cell lung cancer.
38. A kit comprising the bispecific antibody according to any one of claims 1 to 15 and an indicator for detecting the presence of one or more biomarkers specific to a target cell type, tissue or biomolecule in a sample in vitro or in vivo.
39. The kit of claim 38, wherein the indicator comprises a fluorescent dye and a colorimetric dye.
